Efficacy of SGLT2 Inhibitors for Anthracycline-induced Cardiotoxicity: a Meta-analysis in Cancer Patients

Overview

Journal Future Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 4

PMID 38962942

Authors

Sana Mohsin

Misha Hasan

Zubaid Moazzam Sheikh

Fatima Mustafa

Vesna Tegeltija

Sarwan Kumar

Jai Kumar

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower anthracycline-induced cardiotoxicity. PubMed and Google Scholar were searched until September 2023 for studies regarding SGLT2i for treating anthracycline-induced cardiotoxicity. Overall mortality and cardiovascular events were considered. Using a random-effects model, data pooled RR and HR at a 95% confidence interval (CI). 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33-0.82); = 0.005; I= 32%], HF hospitalization [RR = 0.20 (0.04-1.02); = 0.05; I= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20-1.16); = 0.11, I= 0%]. SGLT2i mitigates mortality and hospitalization due to heart failure, improving cancer patient's chances of survival by undergoing anthracycline treatment.

References

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Nakano D, Kawaguchi T, Iwamoto H, Hayakawa M, Koga H, Torimura T . Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS One. 2020; 15(4):e0232283. PMC: 7188283. DOI: 10.1371/journal.pone.0232283. View

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

Eliaa S, Al-Karmalawy A, Saleh R, Elshal M . Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: and Molecular Docking Studies. ACS Pharmacol Transl Sci. 2020; 3(6):1330-1338. PMC: 7737321. DOI: 10.1021/acsptsci.0c00144. View

Heerspink H, Perkins B, Fitchett D, Husain M, Cherney D . Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016; 134(10):752-72. DOI: 10.1161/CIRCULATIONAHA.116.021887. View

Belen E, Canbolat I, Yigitturk G, Cetinarslan O, Akdeniz C, Karaca M . Cardio-protective effect of dapagliflozin against doxorubicin induced cardiomyopathy in rats. Eur Rev Med Pharmacol Sci. 2022; 26(12):4403-4408. DOI: 10.26355/eurrev_202206_29079. View

Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S . SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: A systematic-review and meta-analysis. Vascul Pharmacol. 2023; 150:107171. DOI: 10.1016/j.vph.2023.107171. View

Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z . Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis. JAMA Netw Open. 2022; 5(1):e2142078. PMC: 8733833. DOI: 10.1001/jamanetworkopen.2021.42078. View

Bhagat A, Kleinerman E . Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Adv Exp Med Biol. 2020; 1257:181-192. DOI: 10.1007/978-3-030-43032-0_15. View

10.

Villani L, Smith B, Marcinko K, Ford R, Broadfield L, Green A . The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016; 5(10):1048-1056. PMC: 5034684. DOI: 10.1016/j.molmet.2016.08.014. View

11.

Okada J, Matsumoto S, Kaira K, Saito T, Yamada E, Yokoo H . Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver. Clin Colorectal Cancer. 2017; 17(1):e45-e48. DOI: 10.1016/j.clcc.2017.09.005. View

12.

Volkova M, Russell 3rd R . Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2012; 7(4):214-20. PMC: 3322439. DOI: 10.2174/157340311799960645. View

13.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

14.

Lau K, Ng L, Wong J, Loong H, Chan W, Lee C . Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment - A Review. Rev Endocr Metab Disord. 2021; 22(4):1121-1136. DOI: 10.1007/s11154-021-09675-9. View

15.

Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y . Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity. Molecules. 2020; 25(3). PMC: 7038111. DOI: 10.3390/molecules25030495. View

16.

Saad M . Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study. Ann Transl Med. 2018; 6(3):55. PMC: 5879533. DOI: 10.21037/atm.2017.11.08. View

17.

Horacek J, Jakl M, Horackova J, Pudil R, Jebavy L, Maly J . Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol. 2009; 31(2):115-7. View

18.

Staels B . Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. Am J Med. 2017; 130(6S):S30-S39. DOI: 10.1016/j.amjmed.2017.04.009. View

19.

Sabatino J, De Rosa S, Tamme L, Iaconetti C, Sorrentino S, Polimeni A . Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020; 19(1):66. PMC: 7229599. DOI: 10.1186/s12933-020-01040-5. View

20.

Avula V, Sharma G, Kosiborod M, Vaduganathan M, Neilan T, Lopez T . SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2023; 12(1):67-78. DOI: 10.1016/j.jchf.2023.08.026. View